DNA copy number alterations (CNAs) are a hallmark of cancer that can drive the expression of oncogenes 1 or delete TSGs 2 . Recurrent CNAs that disrupt the same gene can be highly informative, pinpointing oncogenic alterations that may serve as therapeutic targets. More often, CNAs are large, making it difficult to identify which gene(s) are driving transformation. RNA silencing technologies have uncovered new TSGs within large deletions 3 , but approaches to screen the oncogenic capacity of genes located within large regions of gain are less well developed.
Recently, we showed that EPHB2 amplification 4 or C11orf95-RELA translocation 5 -two genetic alterations in the human brain tumor ependymoma-can transform mouse embryonic Cdkn2a-Cdkn2b −/− cerebral neural stem (cNSC null ) cells to generate corresponding tumors in mice. These mouse models are proving useful in developing new treatments for the clinic 6 . The identification of additional ependymoma oncogenes and TSGs might further advance understanding of the disease, but whole-genome and transcriptome sequencing have not detected additional recurrent mutations or focal CNAs in ependymoma 5, 7 . Rather, these tumors are characterized by large CNAs that encompass many genes.
To identify genes that drive ependymoma, we performed a comprehensive in vivo screen of 84 candidate oncogenes and 39 candidate TSGs located within 28 recurrent CNAs. Through a series of mouse models, we identify 8 new ependymoma oncogenes and 10 new ependymoma TSGs that disrupt a limited number of cell functions, including vesicle trafficking and cholesterol synthesis. We propose that these cell functions are important components of ependymoma pathogenesis and may be potential therapeutic targets.
(n = 75/84) of the candidate oncogenes were expressed at ≥10-fold higher levels in the cNSC null pools than in mock-transduced controls (Fig. 2b) , whereas 4% (n = 3/84) of the candidates displayed between 5-and 10-fold higher expression and 7% (n = 6/84) of the candidates were expressed at levels ≤2-fold higher than in controls. We observed similar increases in candidate oncogene expression in hNSC null and sNSC null pools, as well as in cNSC null pools harboring diploid control genes (data not shown).
We separately implanted 1.5 × 10 6 eGFP + YFP + RFP + cells from each cNSC null , hNSC null and sNSC null pool into the cerebrum of individual immunocompromised mice, exactly as described previously 4 (average of 15 mice per pool, range of 11-25; total of 213 mice; Supplementary  Table 4 ). Separate cohorts of mice were similarly implanted with eGFP + YFP + RFP + cNSC null fractions transduced to express diploid control gene (average of 12 mice per gene, range of 9-18; total of 111 mice; TNP02  STX10  GBAS  LOC90835  PHKG2  GADD45  FBXL19  CCT6A  ARRDC2  MYST1  BEST2  ZNF668  RNF40  MAST1  HOOK2  STX4  CAMSAP1   FUS  ZNF646  FBRS  SUMF2  SET1A  JUNB  POL3S   NFIX  RTBDN  CALR  GCDH  VKORC1  HSD3N7  PHKG1  CTF1  ASNA1  SYCE2  ZNF629  LYL2  KCNN1  IER2  PDE4C  RAD23A   Pool 3  Pool 2  Pool 1   EXO1  SERAT3  CTBP1  PSPH  THAP11  FAM53A  SLBP  AKT2  WHSC2  TMEM129  STX1B2  ORAI3  LSM4  LETM1  BCKDK  BCL7C  TTC9B  TRMT1  SLCA95  RAB3A  KLF1  FARSA  ERICH1  CHCHD2   MRSP17  MAP3K10  SRCAP  CACNA1A  MAST3   PRDX2  C19ORF43   PKP3  PRSS36  PRSS8  DAND5  DNASE Supplementary Table 5 ). All 324 mice were imaged twice a month using bioluminescence to detect tumor development. None of the 111 mice carrying cNSC null cells transduced to express diploid control genes or the 86 mice implanted with cNSC null and/or sNSC null pools 5, 7, 9, 10 or 11 developed tumors (median follow-up time of 284 d; Supplementary Tables 4 and 5). Thus, virus-transduced NSC null cells are not intrinsically tumorigenic. Conversely, cNSC null pools 1-4, 6 and 8 generated eGFP + YFP + RFP + tumors with variable penetrance, ranging from 8% (n = 2/25) for pool 6 to 62% (n = 8/13) for pool 3 (Fig. 2c-e ). sNSC null and hNSC null fractions containing the same candidates as cNSC null pool 1 and sNSC null fractions containing the same candidates as cNSC null pool 2 also generated tumors ( Fig. 2d,e ). Therefore, we concluded that the 48 candidates within pools 1-4, 6 and 8 likely include oncogenes.
To detect which of these 48 candidate oncogenes might have driven transformation, we used real-time quantitative PCR (RT-qPCR) to quantify DNA for candidate genes in tumors relative to the corresponding preimplantation cell pools ( Fig. 3a) . DNA for 71% (n = 34/48) of the candidate genes was present in significantly reduced amounts in tumors, supporting the notion that NSC null cells harboring these candidates were outgrown by those containing oncogenes (average 10-fold decrease, range of 1.3-to 1,000-fold decrease; Fig. 3a) . In stark contrast, DNA for one or two candidate oncogenes per pool was selectively and recurrently enriched by ≥2-fold in tumors, indicating that these candidates had likely driven NSC null proliferation in vivo and might be oncogenes (average of 11.6-fold increase, range of >2.2-to >42.7-fold), including AKT2 and PSPH (both pool 1), TMEM129 (pool 2), TTC9B (pool 3), RTBDN (pool 4), RNASEH2 (pool 6) and ARRDC2 (pool 8). In addition, ERICH1 and RAB3A (both pool 3), CTF1 (pool 4), PRDX2 (pool 6) and ZNF668 (pool 8) were enriched by ≥2-fold in a single tumor each, whereas BCL7C (pool 2) and VKORC1 (pool 4) were enriched by between 1-and 2-fold in a single tumor each. Analysis of tumors with sufficient material showed that 75% (n = 6/8) of enriched candidates were also expressed at higher levels in tumors than in the corresponding preimplantation NSC pools, whereas 95% (n = 18/19) of nonenriched candidates displayed unchanged or decreased expression (P < 0.005, Fisher's exact test; Fig. 3a ). Together, these data identified 14 of our initial 84 candidate oncogenes as leads for validation studies.
Pool-derived tumors displayed a variety of morphologies that approximated human high-grade glioma (59%, n = 16/27), primitive neuroectodermal tumor (PNET; 26%, n = 7/27) and ependymoma (15%, n = 4/27; Fig. 3b,c and Supplementary Table 4 ). These data are compatible with the recurrent gain of candidates in a broad range of human cancers ( Fig. 1b) . Indeed, AKT2, which was selectively enriched in high-grade glioma-like pool 1 tumors, promotes the growth, invasion and treatment resistance of human high-grade glioma 9 , whereas TTC9B, which was selectively enriched in pool 3-derived PNET-like tumors, is located on human chromosome 19q, a region recurrently gained in human PNETs.
In vivo validation of ependymoma oncogenes
To validate our lead candidate oncogenes, we transduced 14 new fractions of eGFP + YFP + cNSC null cells with a single lead candidate each and implanted 1.5 × 10 6 of these cells into the cerebrum of separate immunocompromised mice (average of 16 mice per candidate, range of 10-30; total of 209 mice; Fig. 4a and Supplementary  Table 6 ). Additionally, to further test the role of central nervous system (CNS) topography in ependymoma tumorigenesis, we implanted the cerebella of 14 immunocompromised mice with fresh fractions of hNSC null cells harboring AKT2 that were enriched in hNSC null pool 1 tumors and the spines of 10 mice with sNSC null cells harboring TMEM129 that were enriched in sNSC null pool 2 tumors (Figs. 3a and 4a, and Supplementary Table 6 ). We performed 2 other regional tumorigenesis assays: 29 cerebellar implants of hNSC null cells harboring MRPS17, which is highly expressed in posterior 
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A r t i c l e s fossa ependymoma 4 but was not tested in an hNSC null pool, and 6 spinal implants of sNSC null cells harboring RTBDN, which was the most enriched candidate in all the cNSC null pool-derived tumors.
We imaged all 268 mice twice a month using bioluminescence. Of the candidate genes analyzed, 53% (n = 8/15) drove tumors and were therefore validated as neural oncogenes ( Fig. 4a,b and Supplementary Table 6 ). The oncogenes we validated within the cerebrum included ZNF668, which links chromatin relaxation state to DNA repair 10 , and BCL7C, a member of the SWI/SNF chromatin-regulatory complex 11 (both among 23 candidates in the 16p11.2 amplicon; Supplementary Table 1) ; RAB3A, which controls late-stage vesicle trafficking and exocytosis in neuronal cells 12, 13 (among 7 candidates in the 19p13.11 amplicon); the putative oncogene PRDX2, which regulates oxidation-induced apoptosis 14 , and RTBDN, of unknown function (both among 25 candidates in the 19p13.13 amplicon); and the AKT2 oncogene (among 4 candidates in the 19q13.2 amplicon; Fig. 4a ). AKT2 and RTBDN also drove tumorigenesis in the hindbrain and spine, respectively, indicating that these genes are broadly oncogenic in the CNS. We validated TMEM129, of unknown function (among 9 candidates in a 4p16.3 amplicon), and the mitochondrial ribosomal protein MRPS17 (among 7 candidates in the 7p11.2 amplicon) as spinal and hindbrain oncogenes, respectively ( Fig. 4a) . Conversely, ARRDC2, CTF1, ERICH1, PSPH, RNASEH2, TTC9B and VKORC1 did not drive tumors and were therefore not validated as neural oncogenes. Interestingly, the validated oncogenes were tenfold more likely to be gained across human cancers than non-validated candidates, although this difference did not reach significance ( Supplementary Fig. 2) .
In contrast to pool-derived tumors, tumors driven by single candidates never displayed a PNET-like morphology and were three times more likely to be ependymomas (62.5% (n = 20/32) single-candidate versus 18.8% (n = 3/16) pool-derived tumors; P < 0.01, Fisher's exact test; Figs. 3c and 4b) . Thus, our validated candidates are ependymoma oncogenes, and the genetic heterogeneity of the pooled tumors may have contributed to their morphological diversity. Conversely, 93% (n = 14/15) of cerebellar and spinal tumors driven by single candidates were high-grade glioma-like tumors ( Fig. 4b) . Thus, cell context and location may dictate tumor morphology in the CNS.
BCL7C, RAB3A and ZNF668 oncogenes and ependymoma subtype
Human supratentorial ependymomas comprise two molecular subtypes defined by the presence or absence of the C11orf95-RELA translocation 5 . To test which of these subtypes is modeled by our mouse ependymomas driven by validated oncogenes, we compared the transcriptomes of human and mouse cerebral ependymomas positive and negative for the C11orf95-RELA translocation using our Agreement of Differential Expression (AGDEX) algorithm that tests for transcriptomic similarities between tissues from different species 4 . Mouse ependymomas driven by BCL7C, RAB3A and ZNF668 displayed a significant (P < 0.01, permuted P value) match with human ependymoma's negative for C11orf95-RELA translocation, confirming these tumors as faithful models of this subtype of the human disease ( Supplementary Fig. 3) .
To begin to understand the cell processes that are disrupted by ependymoma oncogenes, we used gene set enrichment analysis (GSEA) to compare the transcriptomes of parental cNSC null cells High-grade glioma Ependymoma PNET NA
Candidate gene expression
Tumor
Tumor Tumor First, we generated 117 shRNA-IRES-cyan fluorescence protein (CFP) lentiviruses targeting our 39 candidate TSGs (3 shRNAs per candidate; Supplementary Table 2 ). We then randomly mixed the lentiviral triplets targeting a single candidate to create 4 libraries: libraries 1-3 each contained 30 lentiviruses targeting 10 candidate TSGs, and library 4 included 27 lentiviruses targeting 9 candidate TSGs. We then used each lentivirus library to transduce separate fractions of tumor-prone cNSC null cells transduced with EPHB2 (EPHB2-cNSC null cells) at a multiplicity of infection (MOI) of 1 or 5. Illumina sequencing confirmed equal representation of shRNA sequences within transduced cNSC null cells (Fig. 5b) . We then sorted 1.5 × 10 6 eGFP + YFP + RFP + CFP + EPHB2-cNSC null cells by FACS for each of the eight fractions and implanted them into the cerebra of separate immunocompromised mice (average of 11 mice per fraction, range of 9-13; total of 84 mice; Supplementary Table 8 ).
We implanted a separate cohort of 10 mice with eGFP + YFP + RFP + CFP + EPHB2-cNSC null cells transduced with scrambled control shRNA. We imaged mice weekly using bioluminescence. with those of daughter tumors driven by RAB3A (n = 6), BCL7C (n = 9) and ZNF668 (n = 9) ( Fig. 4c and Supplementary Table 7 ). As expected, almost one-half of the top 200 most positively or negatively enriched gene sets in mouse ependymomas included regulators of cancer processes (n = 52/200), the cell cycle (n = 22/200) or cell signaling (n = 16/200). The remaining enriched gene sets were dominated by a handful of cellular functions that included immune response (23%, n = 23/100), synaptogenesis and vesicle trafficking (11%, n = 11/100), modifications to the epigenome (11%, n = 11/100) and stem cell regulation (4%, n = 4/100). These data are in keeping with the function of RAB3A as a regulator of exocytosis in neural cells 12, 13 and the roles that BCL7C 11 and ZNF668 (ref. 10) have in chromatin modification. Additionally, we and others have previously reported significant upregulation of vesicle trafficking and immune response regulators in human ependymoma 4, 15 . Regulators of DNA repair (8%, n = 8/100) and cholesterol biosynthesis (3%, n = 3/100) were among the most downregulated gene sets in our mouse tumors (Fig. 4c) .
Together, these data identify eight new ependymoma oncogenes located within six recurrent ependymoma CNAs, provide three new models of human ependymoma negative for C11orf95-RELA translocation, and implicate aberrant vesicle trafficking, DNA modification and repair, immune response and cholesterol biosynthesis in ependymoma tumorigenesis.
In vivo screen of candidate ependymoma TSGs
To determine whether our 39 TSG candidates possess tumor-suppressor function, we assessed whether short hairpin RNAs (shRNAs) targeting these genes could cooperate with EPHB2 to transform cNSC null cells (Fig. 5a) . We previously validated EPHB2 as an ependymoma oncogene 4 . 1832  1839  1831  1840  1829  1836  1830  1833  1826  1828  1854  1855  1904  1909  2000  1903  1905  1907  1910  1913  1902  1908  1901  1914  1906  1925  1926  1917  1929  1923  1927  1922  1915  1916  1920  1842  1846  1852  1845  1848  1844  1843 
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As expected, all mice developed tumors 4 . To detect TSGs among our 39 candidates, we first looked in tumors for shRNA sequences that were enriched relative to the corresponding preimplantation, parental EPHB2-cNSC null fraction (average of 3.04 × 10 5 shRNA Illumina sequence reads per tumor; Fig. 5b and Supplementary  Table 8 ). We judged TSG candidates to have been 'targeted' if at least one corresponding shRNA sequence was enriched by ≥4-fold in ≥2 tumors ( Fig. 5b) : 62% (n = 24/39) of the candidates achieved this targeting threshold (and are hereafter referred to as targeted TSG candidates; Fig. 5b) . The targeted TSG candidates identified did not differ significantly between tumors derived from EPHB2-cNSC null cells transduced with an MOI of 1 or 5 (data not shown). One 19) and St13), suggesting that the other 18 targeted candidates might also be TSGs. In keeping with this notion, tumors that had enriched shRNA levels for targeted candidates grew significantly faster than non-enriched tumors (P < 0.05, Mann-Whitney; Fig. 5c ). As expected, shRNAs targeting Cdkn2a and Cdkn2b, which are known ependymoma TSGs but are already deleted from cNSC null cells, were not recurrently enriched.
To further assess targeted TSG candidates, we compared their expression in six tumors that enriched the corresponding shRNA sequences with their expression in non-enriched tumors and the original implanted cNSC null pool (Fig. 5b,d) . Five targeted TSG candidates were expressed in tumors at levels ≥2 s.d. below the levels observed in parental cNSC null cells (the majority of probes reporting expression of Aldh3a1, Actr1a, Snx6, Ulk2 and Pcmt1; Fig. 5d ), whereas four candidates were expressed at levels ≥2 s.d. below those observed in control tumors (the majority of probes reporting expression of Aldh3a1, Snx6, Ulk2 and Pcmt1; Fig. 5d ). Interestingly, targeted TSG candidates were 1.2-fold more likely to be deleted across human cancers than non-validated TSG candidates, although this difference did not reach significance (Supplementary Fig. 2) .
To further validate our TSG screen, we repeated our in vivo tumorigenesis assays but this time compared tumor initiation by EPHB2-cNSC null cells transduced with control shRNAs, Ulk2 shRNAs or Dna2 shRNAs alone. Knockdown of Ulk2 dramatically accelerated the initiation of brain tumors relative to control cells (Fig. 5e) . EPHB2-cNSC null cells transduced with Dna2 shRNAs displayed a marginal increase in tumor growth relative to control cells. Together, these data strongly support ALDH3A1, ACTR1A, SNX6, ULK2 and PCMT1 as new ependymoma TSGs. Because DNA2, SUFU, STAG1, TET1 and ST13 have established TSG functions, we propose that these are also ependymoma TSGs. 18) ), processes that were also disrupted in our oncogene screens ( Fig. 5f and Supplementary Table 9 ). The convergence of our independent oncogene and TSG screens on these common cell functions suggests that they are critical for ependymoma tumorigenesis.
Because gain of RAB3A (19p13.1), which promotes exocytosis 12, 13 , and deletion of multiple targeted TSG candidates that regulate endocytosis (for example, ULK2 and SNX6) were mutually exclusive in human ependymoma, we reasoned that these CNAs might cooperate to disrupt vesicle trafficking ( Figs. 5 and 6a) . Indeed, both excessive exocytosis and defective endocytosis have been implicated in malignant transformation through mistrafficking growth factor receptors to the cell membrane 28, 29 . Therefore, we tested whether upregulation of RAB3A or downregulation of Ulk2 or Snx6 similarly disrupt vesicle trafficking and epidermal growth factor receptor (Egfr) and fibroblast growth factor receptor (Fgfr) signaling in cNSCs, as these receptors have been implicated in ependymoma 6, 30, 31 . We detected significantly more exocytosis-measured using a pH-sensitive exosome-associated fluorescent protein, VAMP7*-in RAB3A-overexpressing cells than in controls, but exocytosis was unaffected by either Ulk2 or Snx6 knockdown (P < 0.0001, Mann-Whitney; Fig. 6b ). Conversely, mean endosome volume-measured using an endosome-specific fluorescent dye-was significantly decreased in cells transduced with Snx6 or Ulk2 shRNAs relative to controls (P < 0.0005, Mann-Whitney; Fig. 6c ). Interestingly, overexpression of RAB3A also reduced endosomal volume, albeit to a lesser degree. In concert with this disruption in vesicle trafficking, upregulation of RAB3A or depletion of either Ulk2 or Snx6 prolonged both Egfr and Fgfr signaling via the Mek-Erk pathway in cNSCs (Fig. 6d) . Furthermore, mouse cerebral ependymoma cells proved to be selectively sensitive to growth inhibition by the pan-Fgfr inhibitor BGJ398 in comparison to cNSC null cells (Fig. 6e) . Thus, we propose that ependymoma CNAs cooperate to dysregulate the trafficking of oncogenic growth factor receptors.
As well as disrupting vesicle trafficking, our validated, CNA-associated oncogenes generated ependymomas with diminished amounts of cholesterol biosynthesis machinery (Figs. 4c and 7a) . Whether this is a cause or consequence of cNSC transformation is unclear, but statin-mediated inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), a critical enzyme in cholesterol biosynthesis, has been reported to prevent 32 and treat 33 brain tumors. Therefore, we reasoned that the downregulation of cholesterol biosynthesis in ependymoma cells might render them susceptible to further pathway suppression. In keeping with this notion, six different statins markedly and selectively impaired the proliferation of mouse cerebral ependymoma cells in comparison to parental cNSC null cells and a variety of other brain tumor and control cell lines (Fig. 7b) .
DISCUSSION
We report the identification of 8 new ependymoma oncogenes and 10 new ependymoma TSGs from among 123 genes located within 28 recurrent CNAs. These genes emerged from screens of oncogenes and TSGs that converged on just a handful of cell functions, providing new animal models of ependymoma and insights into disease biology and treatment. 
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A r t i c l e s As well as providing new insights into brain oncogenesis and treatment, the results of our screens also pose some key questions: for example, why did some of the most enriched candidate oncogenes emerging from our screen of cNSC pools (for example, ARRDC2 and RNASE2H) fail to drive tumors when transduced alone into cNSCs and why did tumors with pooled oncogenes but not those driven by single oncogenes include PNET-like tumors? Further work will be required to answer these questions, but one possibility is that certain oncogenes only drive transformation in the context of clonal heterogeneity, perhaps requiring paracrine factors from surrounding, but unrelated tumor cells. Indeed, pool-derived tumors that enriched ARRDC2 and RNASE2H also enriched the validated oncogenes ZNF668 and PRDX2, respectively. Clonal heterogeneity might also explain the variety of histologies that we observed among tumors derived from pooled fractions. But it is also important to consider whether the ex vivo manipulation and implantation of NSCs that was used to generate our models affects tumor morphology. Finally, an important caveat of our oncogene screening approach was that only one TSG locus was deleted in these studies (Cdkn2a-Cdkn2b null). CDKN2A-CDKN2B is deleted in ~50% of human cerebral ependymomas 4 but is rarely deleted from hindbrain or spinal tumors. Thus, pairing oncogene candidates with alternative TSGs might validate additional oncogenes.
In summary, we describe a new and comprehensive cross-species approach to identify oncogenes and TSGs within recurrent tumor CNAs. The approach described here could be applied to other cancers, enabling the identification of critical oncogenic drivers in tumors that lack recurrent alterations of single genes. 
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We are grateful to F.B. Gertler (Massachusetts Institute of Technology) and S. Gupton (University of North Carolina) for the generous gift of the VAMP7phlorin construct and the staffs of the Hartwell Center for Bioinformatics and Biotechnology, the Small Animal Imaging Center, the Animal Resources Center, the Cell and Tissue Imaging Center, and the Flow Cytometry and Cell Sorting Shared Resource at St. Jude Children's Research Hospital for technical assistance. Aberrant vesicle trafficking is thought to transform cells by disrupting the recycling of growth factor receptors, prolonging cell signaling and abolishing cell polarity 28, 29 . For example, disruption of Rab25, which regulates various aspects of vesicle trafficking, promotes intestinal tumorigenesis in mice 34 , and the endosome regulators Rbsn, Vps45, Avl and Rab5 serve as TSGs in Drosophila melanogaster 35 . Dysregulation of vesicle trafficking has also been observed in human cancer, although most studies report altered expression rather than mutation of vesicle trafficking genes, making it difficult to determine whether it is a cause or consequence of human malignancy 28, 29 . Our data provide evidence that ependymoma CNAs amplify pro-exocytotic oncogenes and delete pro-endocytotic TSGs, driving the mistrafficking of growth factor receptors in cNSCs. In this regard, we validated RAB3A as a new brain tumor oncogene. Although Rab3a is a known regulator of late-stage vesicle trafficking in neuronal cells 12, 13 , subsequent modulation of growth factor receptor signaling has not been reported. We also identified seven CNA-associated TSGs that populate key points in the receptor endocytosis pathway: ULK2 (deleted from 17p11.2) positively regulates receptor endocytosis in neural cells 20 , whereas SGSM3 (22q13.1) binds Rab proteins in endosomes that orchestrate endocytosis 21 . Receptors within endosomes are then recycled to the trans-Golgi network by the retromer, a heteropentameric protein complex that includes SNX6 (14q13.1). SNX6 organizes the retromer within the endosomal network by mediating direct interactions with the dynactin subunit p150glued 22 . p150glued binds an additional dynactin subunit, ACTR1A 23 (10q24.32). Recycling of receptor endosomes is further regulated by AKAP10 (17p11.2), which binds Rab4-or Rab11-labeled vesicles 24 , PRKRA2A (3p21.31) and TOR1A-TOR1B (9q34.11) 25 . Our observation that gain of RAB3A or deletion of Snx6 or Ulk2 prolongs Egfr and Fgfr signaling in cNSCs supports the notion that CNAs promote the trafficking of oncogenic receptors to the surface of ependymoma cells.
We also identified new ependymoma oncogenes (BCL7C and ZNF668) and TSGs (TET1, CDK19, STAG1 and DNA2) that regulate chromatin modification and remodeling or telomere maintenance. These data are particularly interesting as aggressive forms of ependymoma possess aberrant chromatin states 7 and dysfunctional telomeres 36 : BCL7C is a close relative of the lymphoma translocation partner BCL7A 37 and a subunit of the nucleosome-remodeling SWI/SNF complex 11 ; ZNF668 links chromatin relaxation state with the DNA damage response 10 ; TET1 is a known TSG that converts 5-methylcytosine into 5-hydroxymethylcytosine 18 ; and CDK19 represses C/EPβ target gene transcription 27 . With regard to telomere function, STAG1 encodes a component of the cohesin complex that is essential for telomere cohesion 26 , and DNA2 recognizes and cleaves telomeric G4, protecting cells from chromosome segregation errors 16 .
One surprising result of our study was the observation that ependymomas driven by each validated oncogene downregulate cholesterol biosynthesis, rendering the tumors highly sensitive to further pathway suppression. This phenomenon might also involve mistrafficking of oncogenic receptors. Endocytosed receptors face two alternative fates: recycling back to the cell membrane (clatherinmediated endocytosis, or CME) or degradation (non-clatherin mediated endocytosis, or NCE). NCE is acutely dependent on cholesterol, and disruption of cholesterol supplies pushes EGFR toward CME, recycling receptors to the cell membrane and prolonging EGFR signaling 38 . Thus, downregulation of cholesterol synthesis in transforming cNSCs might promote oncogenic EGFR signaling but render these cells sensitive to further pathway inhibition. npg microarray and deep sequencing studies. K.W. assisted with human genomic analyses. K.G. and D.W.E. conducted all neuropathological reviews. A.O.T. conducted all statistical analyses. R.J.G. conceived, designed and oversaw the study. All authors contributed to writing of the manuscript.
ONLINE METHODS
Human genomic analysis. Our original set of 85 candidate oncogenes and 39 candidate TSGs was identified and reported previously by integrating the results of Affymetrix GeneChip Human Mapping 500K and U133 Plus 2.0 microarrays of human ependymomas 4 . Ninety-eight percent (n = 83/85) of the candidate oncogenes screened in the current study were selected from an original list of 85 candidates reported in ref. 4 (the "subgroup-specific expression" column of Supplementary Table 5a included genes that displayed copy number-driven expression within a specific genomic subgroup of ependymoma rather than generally across the disease). Note that LOC90835 and POL3S have since been renamed C16orf93 and PRSS53, respectively. The cDNA for NACC1 reported as a candidate oncogene in ref. 4 was not commercially available when we initiated our study, and LOC730744 has since been withdrawn from the RefSeq database. These two genes were therefore replaced by EXO1, which was highly amplified in cerebral ependymoma (confirmed by FISH; data not shown), and FAM53A, which is present in the 4p16.3 ependymoma amplicon.
The 39 candidate TSGs were all drawn from 130 candidates identified as deleted in ref. 4 ( Supplementary Table 5b ). These 130 TSG candidates were selected for screening on the basis of evidence of subtype-specific copy number-driven expression (as for oncogenes) but also on the basis of evidence of candidate involvement in at least two of the following processes: neural development, cancer (general) and brain tumors (see Supplementary  Table 2 for more details). Seventy-seven percent (n = 30/39) of the candidate TSGs selected for screening displayed both copy number-driven decreased expression in ependymoma and evidence of involvement in 2 or more of the processes defined above. We selected four additional candidate TSGs for screening because they were located within one of the most recurrent minimal deletion regions in ependymoma (on chromosome 22q13.1), and five candidates were screened because of published evidence implicating them in neural development, cancer (general) or brain tumors (see Supplementary  Table 2 for details).
Two methods were used to assess the relative gain or loss of candidate oncogenes and TSGs in human cancers. We used the cBioPortal (see URLs) web resource to obtain allelic gain and loss data from 15,752 samples of 17 different types of human cancer, which are approved for use from the TCGA through cBioPortal. For each tumor type, the ratio of gain to loss for candidates was recorded. We used the COSMIC database (see URLs) to calculate the net gain or loss for each candidate oncogene and TSG in 3,116 samples of 9 different human cancers. In both analyses, the Mann-Whitney test was used to assess the significance of the difference in relative gain or loss of candidate oncogenes and TSGs.
Generation of candidate oncogene retroviruses. Retroviral plasmids containing the ORF of each candidate oncogene were generated by subcloning into the pCX4-IRES-Red vector. cDNA clones for each candidate oncogene were obtained from a variety of sources, including the American Type Culture Collection (ATCC), Invitrogen, Open Biosystems, Addgene, GeneCopoeia and Origene, or were generated in house by RT-PCR. The sequence of all cloned inserts was verified by Sanger sequencing. Retroviral plasmids were then transfected together with pMD-old-gag-pol and CAG4-Eco plasmids into 293T cells (ATCC; negative for mycoplasma). After 20 h, the medium was exchanged for serum-free neurobasal medium (Invitrogen) containing 2 mM l-glutamine, N2 supplement (Invitrogen), B27 supplement (Invitrogen), 20 ng/ml recombinant human epidermal growth factor (EGF; Invitrogen), 20 ng/ml recombinant human basal fibroblast growth factor (bFGF; Invitrogen) and 50 µg/ml BSA. Every subsequent 8-10 h, virus-containing medium was collected for up to 3 d. Virus-containing medium was centrifuged, filtered (0.45-µm filter, Millipore) and concentrated using Centricon Plus-70 filter units (Millipore). Viral titers were calculated by assessing transduction efficiency at different dilutions in NIH3T3 cells (ATCC; negative for mycoplasma).
Preparation of NSCs transduced to express candidate oncogene pools.
All mouse studies were performed according to protocols approved by the St. Jude Children's Research Hospital Animal Care and Use Committee (equal numbers of male and female mice were used). eGFP + NSCs were isolated from embryonic day (E) 14.5 cerebrum (cNSC null ) and hindbrain (hNSC null ) and adult (postnatal day (P) 60) spine (sNSC null ) from Fabp7-eGFP; Cdkn2a-Cdkn2b −/− mice exactly as described previously 4 . Briefly, forebrain, hindbrain and spine samples macrodisected from embryonic and adult mice were minced and digested separately with collagenase type IV and hyaluronidase, and the cells isolated were cultured in neurobasal medium 4 . We have shown previously that cells cultured in this manner are almost all (~100%) self-renewing eGFP + NSCs (demonstrated previously using serial potency assays; ref. 4). NSC null cells were then transduced with a luciferase-IRES-YFP retrovirus to allow for bioluminescence imaging of cells in vivo. eGFP + YFP + cNSC null cells were then isolated by FACS and separated into 84 fractions. Although cell sorting does not completely resolve the eGFP + YFP + and eGFP + YFP − cNSC null populations, our lenitviral transductions were highly efficient, leading to consistent transduction of >80% of eGFP + cells 4 . Each fraction was transduced with one of the 84 retroviruses, each encoding a different candidate oncogene upstream of an IRES-RFP reporter. The eGFP + YFP + RFP + cNSC null cells were then sorted from each fraction and randomly mixed together in equal proportions, creating 11 cell pools each comprising mixtures of cells that each carried one of up to 8 different candidate oncogenes ( Fig. 2a,b) . Thus, cell pools comprised mixtures of NSC populations that each carried a single candidate oncogene rather than cNSCs carrying multiple candidate oncogenes ( Fig. 2a) . This pool design served as the basis of our in vivo tumorigenesis screen that was predicated on the notion that cNSCs within pools that carried oncogenic candidate genes would outgrow cNSCs in pools that were transduced with non-oncogenic candidate genes.
Generation of candidate tumor-suppressor gene shRNA lentiviral pools.
Three 19-mer shRNAs targeting each candidate TSG were designed using the shRNA sequence prediction algorithm from Dharmacon/Thermo Scientific (see URLs). shRNAs were cloned into the pFUGWH1-CFP vector and transformed into bacteria as one ligation product. The transformed bacteria were then spread on an LB plate with ampicillin selection, and individual colonies were screened for unique shRNA constructs by sequencing. All 117 constructs were verified by sequencing. shRNAs were then pooled as concentration-normalized DNA mixtures. This equimolar DNA mix was used to transform bacteria, and the mixed-population bacterial culture was expanded, collected and subjected to endotoxin-free DNA maxiprep. Before DNA maxiprep, a sample of the bacteria was streaked on an LB plate with ampicillin selection, and individual colonies were screened for unique shRNA constructs to verify that pool complexity was maintained. The DNA mix was transfected into 293FT cells (Invitrogen) along with lentiviral packaging plasmids for viral production using FuGENE (Roche). Resulting virus titer was determined by examining CFP expression in transduced E14.5 cNSC null cells. Finally, ependymomaprone cNSC null cells transduced with EPHB2 and luciferase were mass transduced with pools of shRNA lentivirus at an MOI of 1 or 5. Transduced cNSC null cells were then expanded through one passage. A sample of cells was then taken for deep sequencing, and 1.5 × 10 6 of the remaining transduced cells suspended in 5 µl of Matrigel were implanted into the cerebrum of CD-1 nude mice. Tumor growth was monitored by bioluminescence xenogen imaging.
Orthotopic cerebral, cerebellar and spinal NSC implants.
Appropriately transduced NSCs were resuspended in Matrigel at a concentration of 1.5 × 10 6 cells/5 µl and injected using a Hamilton syringe into the cerebral cortex or cerebellum of CD-1 nu/nu immunocompromised female P60 mice with the support of a small-animal stereotactic frame as described 4 . Mice were monitored daily for neurological symptoms and imaged biweekly using bioluminescence. Symptomatic mice were euthanized, and the brain was removed and subjected to direct fluorescence microscopy to detect the presence of GFP + RFP + tumors. Tumors were macrodissected and subjected to three separate preparations. One portion of tissue was flash frozen in liquid nitrogen for RNA and DNA analysis. A second adjacent portion of tissue was fixed in formalin and embedded in paraffin wax. Wax-embedded tissues were sectioned at a thickness of 5 µm and mounted on SuperfrostPlus microscope slides (Fisher Scientific). Staining with hematoxylin and eosin (Fisher Scientific) of dewaxed and rehydrated sections was performed according to a standard protocol. Standard immunohistochemical methods were used to detect proteins in tissue sections. Third, suspensions of live cells were prepared from the remaining tumor fragments and cultured in neurobasal medium. npg conjugate were imaged using a Nikon C2 confocal microscope with a Plan Fluor 40× 1.3 NAO objective, and processing of images was performed with NIS Elements software.
Exocytosis assays were performed using the Neon transfection system at a cell density of 100,000 cells per well, and 0.5 µg of VAMP7-phlorin construct (a generous gift from F.B. Gertler and S. Gupton). The 10-µl Neon tip was used with resuspension buffer R and optimized parameters that included a pulse voltage of 1,200 V, a pulse width of 20 and a pulse number of 2. Cells were plated on the Labtek-Tek II chambered 1.5 German cover glass system in medium without antibiotics. After 24 h, images were acquired with a Zeiss LSM 780 NLO confocal microscope using an LDC-Apochromat 40×NA 1.1W objective or with a Nikon C2 confocal microscope using a Plan Fluor 40× 1.3 NA oil objective, and all images were analyzed and quantified using Fiji software. npg
